Eribulin Monoclonal Antibody

Cat.#: 176729

Size:

Special Price 322.6 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Eribulin Monoclonal Antibody
  • Documents
  • Description
    Product has been tested in direct ELISA.
  • Tested applications
    ELISA
  • Species reactivity
    Chemical
  • Isotype
    Mouse IgG1, κ
  • Preparation
    Eribulin conjugated with BSA. Protein G affinity purified
  • Clonality
    Monoclonal
  • Formulation
    PBS(pH7.4), lyophilized. Reconstitution: Adding sterile water, prepare a stock solution of 2.0 mg/ml.
  • Storage instructions
    Store at -20℃. Avoid freeze / thaw cycles.
  • Applications
    ELISA: 1:5,000-1:20,000
  • Validations

    ELISA Binding Assay of Anti-Eribulin Antibody to different proteins.

    ELISA Binding Assay of Anti-Eribulin Antibody to different proteins.

    ELISA analysis of Anti-Eribulin Monoclonal Antibody with Eribulin-BSA, Eribulin-OVA , BAS and OVA. Anti-Eribulin Monoclonal Antibody can bind to Eribulin-BSA or Eribulin-OVA but not carrier proteins.

    ELISA Binding Assay of Anti-Eribulin Antibody

    ELISA Binding Assay of Anti-Eribulin Antibody

    Immobilized Eribulin ADC at 2μg/mL (100μL/well) can bind anti-Eribulin mouse monoclonal antibody.

  • Background
    Eribulin is a synthetic analogue of halichondrin B which is a large polyether macrolide derived from a very strong natural mitotic tubule inhibitor. Eribulin acts by inhibiting the dynamics of the microtubules. It binds to the plus ends of the microtubules and suppresses the microtubule growth in the interphase cells without affecting the shortening phase and sequesters tubulin into nonproductive aggregates, leading to G2/M cell-cycle block and ultimately apoptosis after prolonged mitotic blockage. Its mechanism is distinct from other microtubule inhibitors like vinca alkaloids and taxanes, which affect both the shortening and growing phases.
  • References
    • Watanabe K, Yui Y, Sasagawa S, Suzuki K, Kanamori M, Yasuda T, Kimura T. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4;10(2):161-174. doi: 10.18632/oncotarget.26536. PMID: 30719211; PMCID: PMC6349434.
    • Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008 Jul;7(7):2003-11. doi: 10.1158/1535-7163.MCT-08-0095. PMID: 18645010; PMCID: PMC2562299.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"